Barinthus Biotherapeutics plc announced that its Board determined the Scheme Exchange Ratio for its proposed all-stock combination with Clywedog Therapeutics to be 0.111, ensuring Topco's common stock meets Nasdaq's minimum price requirements. The scheme of arrangement is expected to become effective on September 3, 2026, at which point Barinthus Bio will delist its American Depositary Shares from Nasdaq and halt trading prior to the market open. Following the transaction, Topco will be renamed Clywedog Therapeutics Holdings, Inc., with common stock listed under the ticker symbol "CLYD." The company's application for the scheme is scheduled to be heard by a High Court Judge in London on September 1, 2026. Barinthus Biotherapeutics plc operates as a clinical-stage biopharmaceutical company developing immunotherapeutic candidates for autoimmunity and chronic infectious diseases.
